GleamWall
中文EN

CPMV Mosaic ImmunoEngineering Inc.

Biological Products, (No Diagnostic Substances) · OTC · SEC CIK 836564 · Fiscal year ends 12/31

Financial factors as of 2026-06-30 (2026Q2), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY0.8%
TTM EPS YoY0.0%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE—
ROA-2,254.4%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets238,930.6%
Debt / equity—
Current ratio0.00x
Interest coverage-60.40x

Cash quality & payout

Operating cash flow / net income0.08x
Accruals ratio-2,078.8%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue——
R&D expense$63,981$183,867
SG&A expense$552,138$695,788
Operating income-$616,119-$879,655
Interest expense$10,001$6,954
Pretax income-$685,446-$919,583
Income tax$2,400$2,400
Net income-$687,846-$921,983
EPS (basic)-0.10-0.13
EPS (diluted)-0.10-0.13
Weighted avg. shares (diluted)—7.24M
Balance sheet
Cash & equivalents$3,622$115,019
Current assets$19,882$141,611
Total assets$19,882$141,611
Current liabilities$6.03M$5.54M
Total liabilities$7.50M$6.93M
Shareholders' equity-$7.48M-$6.79M
Shares outstanding7.24M7.24M
Cash flow statement
Operating cash flow-$111,397-$241,159
Investing cash flow—$0
Financing cash flow$0$200,000
Stock-based compensation$0$4,867

Free plan shows the latest 2 periods; Pro shows all 15 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.